No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 21.3x · 10Y median 29.3x · 34th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 24
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T16:27:31.377Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Lucid Diagnostics Inc. (LUCD) stock was $0.61 as of Oct 6, 2026, 12:25 PM EDT, up 2.43% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -42.8% · 3-year avg -22.0%/yr
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions.
Medical - Devices · New York City, NY
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.04
Revenue Est.
$1.63M
Last Quarter Results
EPS
$-0.06
vs Estimate
$-0.06
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1LUCD | $115.93M | $0.61 | +2.43% | -42.80% | N/A | N/A | N/A |
| 2BGM | $116.34M | $9.17 | -1.93% | -96.69% | N/A | N/A | vs LUCD |
| 3GNLX | $116.80M | $2.60 | +0.18% | -41.42% | N/A | N/A | vs LUCD |
| 4COYA | $116.83M | $4.98 | +2.69% | -20.40% | N/A | N/A | vs LUCD |
| 5CRBU | $117.03M | $1.18 | -0.84% | -47.42% | -44.43% | N/A | vs LUCD |
| 6FHTX | $114.20M | $1.95 | -2.75% | -56.72% | -31.87% | N/A | vs LUCD |
forward FY estimate
N/A
$1.47M
vs Estimate
$1.43M
Consensus Rating
Based on 5 analysts
Average Price Target
$4.00
+558.2% upside
Low
$2.00
Current
$0.61
High
$9.50
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.07 | $-0.06 | $-0.05 | 2 |
| Quarter ending Dec 2026 | $-0.06 | $-0.06 | $-0.05 | 2 |
| Quarter ending Mar 2027 | $-0.05 | $-0.05 | $-0.04 | 1 |
| Quarter ending Jun 2027 | $-0.05 | $-0.05 | $-0.04 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.39 | $-0.27 | $-0.17 | 2 |
| FY 2027 | $-0.27 | $-0.18 | $-0.12 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.46M | $1.63M | $1.85M | 3 |
| Quarter ending Dec 2026 | $1.74M | $1.95M | $2.21M | 3 |
| Quarter ending Mar 2027 | $2.53M | $2.83M | $3.20M | 1 |
| Quarter ending Jun 2027 | $3.12M | $3.49M | $3.95M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $4.53M | $6.31M | $8.55M | 3 |
| FY 2027 | $12.01M | $16.71M | $22.65M | 3 |
